Publication: The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
dc.contributor.author | Gayarre, Javier | |
dc.contributor.author | Kamieniak, Marta M | |
dc.contributor.author | Cazorla-Jiménez, Alicia | |
dc.contributor.author | Muñoz-Repeto, Ivan | |
dc.contributor.author | Borrego, Salud | |
dc.contributor.author | García-Donas, Jesús | |
dc.contributor.author | Hernando, Susana | |
dc.contributor.author | Robles-Díaz, Luis | |
dc.contributor.author | García-Bueno, José M | |
dc.contributor.author | Ramón Y Cajal, Teresa | |
dc.contributor.author | Hernández-Agudo, Elena | |
dc.contributor.author | Heredia Soto, Victoria | |
dc.contributor.author | Márquez-Rodas, Ivan | |
dc.contributor.author | Echarri, María José | |
dc.contributor.author | Lacambra-Calvet, Carmen | |
dc.contributor.author | Sáez, Raquel | |
dc.contributor.author | Cusidó, Maite | |
dc.contributor.author | Redondo, Andrés | |
dc.contributor.author | Paz-Ares, Luis | |
dc.contributor.author | Hardisson, David | |
dc.contributor.author | Mendiola, Marta | |
dc.contributor.author | Palacios, José | |
dc.contributor.author | Benítez, Javier | |
dc.contributor.author | García, María José | |
dc.date.accessioned | 2023-01-25T08:36:04Z | |
dc.date.available | 2023-01-25T08:36:04Z | |
dc.date.issued | 2015-11-27 | |
dc.description.abstract | We aimed to evaluate the prognostic and predictive value of the nucleotide excision repair-related gene GTF2H5, which is localized at the 6q24.2-26 deletion previously reported by our group to predict longer survival of high-grade serous ovarian cancer patients. In order to test if protein levels of GTF2H5 are associated with patients' outcome, we performed GTF2H5 immunohistochemical staining in 139 high-grade serous ovarian carcinomas included in tissue microarrays. Upon stratification of cases into high- and low-GTF2H5 staining categories (> and ≤ median staining, respectively) Kaplan-Meier and log-rank test were used to estimate patients' survival and assess statistical differences. We also evaluated the association of GTF2H5 with survival at the transcriptional level by using the on-line Kaplan-Meier plotter tool, which includes gene expression and survival data of 855 high-grade serous ovarian cancer patients from 13 different datasets. Finally, we determined whether stable short hairpin RNA-mediated GTF2H5 downregulation modulates cisplatin sensitivity in the SKOV3 and COV504 cell lines by using cytotoxicity assays. Low expression of GTF2H5 was associated with longer 5-year survival of patients at the protein (hazard ratio [HR], 0.52; 95% CI, 0.29 to 0.93; p=0.024) and transcriptional level (HR, 0.80; 95% CI, 0.65 to 0.97; p=0.023) in high-grade serous ovarian cancer patients. We confirmed the association with 5-year overall survival (HR, 0.55; 95% CI, 0.38 to 0.78; p=0.0007) and also found an association with progression-free survival (HR, 0.72; 95% CI, 0.54 to 0.96; p=0.026) in a homogenous group of 388 high-stage (stages III-IV using the International Federation of Gynecology and Obstetrics staging system), optimally debulked high-grade serous ovarian cancer patients. GTF2H5-silencing induced a decrease of the half maximal inhibitory concentration upon cisplatin treatment in GTF2H5-silenced ovarian cancer cells. Low levels of GTF2H5 are associated with enhanced prognosis in high-grade serous ovarian cancer patients and may contribute to cisplatin sensitization. | |
dc.identifier.doi | 10.3802/jgo.2016.27.e7 | |
dc.identifier.essn | 2005-0399 | |
dc.identifier.pmc | PMC4695457 | |
dc.identifier.pmid | 26463438 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695457/pdf | |
dc.identifier.unpaywallURL | https://doi.org/10.3802/jgo.2016.27.e7 | |
dc.identifier.uri | http://hdl.handle.net/10668/10405 | |
dc.issue.number | 1 | |
dc.journal.title | Journal of gynecologic oncology | |
dc.journal.titleabbreviation | J Gynecol Oncol | |
dc.language.iso | en | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | e7 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Multicenter Study | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.rights | Attribution-NonCommercial 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | 6q24-26 Deletion | |
dc.subject | Cisplatin-Sensitivity | |
dc.subject | DNA Repair | |
dc.subject | GTF2H5 | |
dc.subject | Ovarian Epithelial Cancer | |
dc.subject | Survival | |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Carcinoma, Ovarian Epithelial | |
dc.subject.mesh | Cystadenocarcinoma, Serous | |
dc.subject.mesh | Female | |
dc.subject.mesh | Gene Expression Regulation, Neoplastic | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Kaplan-Meier Estimate | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Grading | |
dc.subject.mesh | Neoplasm Proteins | |
dc.subject.mesh | Neoplasms, Glandular and Epithelial | |
dc.subject.mesh | Ovarian Neoplasms | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Transcription Factors | |
dc.subject.mesh | Tumor Cells, Cultured | |
dc.title | The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 27 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1